[1]
Wanner C, Arad M, Baron R, Burlina A, Elliott PM, Feldt-Rasmussen U, Fomin VV, Germain DP, Hughes DA, Jovanovic A, Kantola I, Linhart A, Mignani R, Monserrat L, Namdar M, Nowak A, Oliveira JP, Ortiz A, Pieroni M, Spada M, Tylki-Szymańska A, Tøndel C, Viana-Baptista M, Weidemann F, Hilz MJ. European expert consensus statement on therapeutic goals in Fabry disease. Molecular genetics and metabolism. 2018 Jul:124(3):189-203. doi: 10.1016/j.ymgme.2018.06.004. Epub 2018 Jun 12
[PubMed PMID: 30017653]
Level 3 (low-level) evidence
[2]
Lenders M, Brand E. Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease. Journal of the American Society of Nephrology : JASN. 2018 Sep:29(9):2265-2278. doi: 10.1681/ASN.2018030329. Epub 2018 Aug 9
[PubMed PMID: 30093456]
[3]
Wasserstein MP, Caggana M, Bailey SM, Desnick RJ, Edelmann L, Estrella L, Holzman I, Kelly NR, Kornreich R, Kupchik SG, Martin M, Nafday SM, Wasserman R, Yang A, Yu C, Orsini JJ. The New York pilot newborn screening program for lysosomal storage diseases: Report of the First 65,000 Infants. Genetics in medicine : official journal of the American College of Medical Genetics. 2019 Mar:21(3):631-640. doi: 10.1038/s41436-018-0129-y. Epub 2018 Aug 10
[PubMed PMID: 30093709]
Level 3 (low-level) evidence
[4]
Chan B, Adam DN. A Review of Fabry Disease. Skin therapy letter. 2018 Mar:23(2):4-6
[PubMed PMID: 29562089]
Level 3 (low-level) evidence
[5]
Del Pino M, Andrés A, Bernabéu AÁ, de Juan-Rivera J, Fernández E, de Dios García Díaz J, Hernández D, Luño J, Fernández IM, Paniagua J, Posada de la Paz M, Rodríguez-Pérez JC, Santamaría R, Torra R, Ambros JT, Vidau P, Torregrosa JV. Fabry Nephropathy: An Evidence-Based Narrative Review. Kidney & blood pressure research. 2018:43(2):406-421. doi: 10.1159/000488121. Epub 2018 Mar 16
[PubMed PMID: 29558749]
Level 3 (low-level) evidence
[6]
Ortiz A, Germain DP, Desnick RJ, Politei J, Mauer M, Burlina A, Eng C, Hopkin RJ, Laney D, Linhart A, Waldek S, Wallace E, Weidemann F, Wilcox WR. Fabry disease revisited: Management and treatment recommendations for adult patients. Molecular genetics and metabolism. 2018 Apr:123(4):416-427. doi: 10.1016/j.ymgme.2018.02.014. Epub 2018 Feb 28
[PubMed PMID: 29530533]
[7]
Sweet ME, Mestroni L, Taylor MRG. Genetic Infiltrative Cardiomyopathies. Heart failure clinics. 2018 Apr:14(2):215-224. doi: 10.1016/j.hfc.2017.12.003. Epub
[PubMed PMID: 29525649]
[8]
Schuller Y, Arends M, Körver S, Langeveld M, Hollak CEM. Adaptive pathway development for Fabry disease: a clinical approach. Drug discovery today. 2018 Jun:23(6):1251-1257. doi: 10.1016/j.drudis.2018.02.004. Epub 2018 Feb 15
[PubMed PMID: 29455022]
[9]
Kubo T. Fabry disease and its cardiac involvement. Journal of general and family medicine. 2017 Oct:18(5):225-229. doi: 10.1002/jgf2.76. Epub 2017 May 8
[PubMed PMID: 29264031]
[10]
Ferreira CR, Gahl WA. Lysosomal storage diseases. Translational science of rare diseases. 2017 May 25:2(1-2):1-71. doi: 10.3233/TRD-160005. Epub 2017 May 25
[PubMed PMID: 29152458]
[11]
Baig S, Vijapurapu R, Alharbi F, Nordin S, Kozor R, Moon J, Bembi B, Geberhiwot T, Steeds RP. Diagnosis and treatment of the cardiovascular consequences of Fabry disease. QJM : monthly journal of the Association of Physicians. 2019 Jan 1:112(1):3-9. doi: 10.1093/qjmed/hcy120. Epub
[PubMed PMID: 29878206]
[12]
Madsen CV, Christensen EI, Nielsen R, Mogensen H, Rasmussen ÅK, Feldt-Rasmussen U. Enzyme Replacement Therapy During Pregnancy in Fabry Patients : Review of Published Cases of Live Births and a New Case of a Severely Affected Female with Fabry Disease and Pre-eclampsia Complicating Pregnancy. JIMD reports. 2019:44():93-101. doi: 10.1007/8904_2018_129. Epub 2018 Aug 17
[PubMed PMID: 30117110]
Level 3 (low-level) evidence
[13]
Fukuda Y, Onishi T, Suzuki A, Tanaka H, Fukuzawa K, Yoshida A, Kawai H, Hirata KI. Follow-up of Cardiac Fabry Disease Treated by Cardiac Resynchronization Therapy. CASE (Philadelphia, Pa.). 2017 Aug:1(4):134-137. doi: 10.1016/j.case.2017.04.004. Epub 2017 Jul 6
[PubMed PMID: 30062265]
Level 3 (low-level) evidence
[14]
Arends M, Wijburg FA, Wanner C, Vaz FM, van Kuilenburg ABP, Hughes DA, Biegstraaten M, Mehta A, Hollak CEM, Langeveld M. Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease. Molecular genetics and metabolism. 2017 Jun:121(2):157-161. doi: 10.1016/j.ymgme.2017.05.001. Epub 2017 May 4
[PubMed PMID: 28495078]
[15]
Lenders M, Hennermann JB, Kurschat C, Rolfs A, Canaan-Kühl S, Sommer C, Üçeyler N, Kampmann C, Karabul N, Giese AK, Duning T, Stypmann J, Krämer J, Weidemann F, Brand SM, Wanner C, Brand E. Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease. Orphanet journal of rare diseases. 2016 Jun 29:11(1):88. doi: 10.1186/s13023-016-0473-4. Epub 2016 Jun 29
[PubMed PMID: 27356758]
Level 3 (low-level) evidence
[16]
Ersözlü S, Desnick RJ, Huynh-Do U, Canaan-Kühl S, Barbey F, Genitsch V, Mueller TF, Cheetham M, Flammer AJ, Schaub S, Nowak A. Long-term Outcomes of Kidney Transplantation in Fabry Disease. Transplantation. 2018 Nov:102(11):1924-1933. doi: 10.1097/TP.0000000000002252. Epub
[PubMed PMID: 29688992]
[17]
Siegenthaler M, Huynh-Do U, Krayenbuehl P, Pollock E, Widmer U, Debaix H, Olinger E, Frank M, Namdar M, Ruschitzka F, Nowak A. Impact of cardio-renal syndrome on adverse outcomes in patients with Fabry disease in a long-term follow-up. International journal of cardiology. 2017 Dec 15:249():261-267. doi: 10.1016/j.ijcard.2017.09.027. Epub 2017 Sep 19
[PubMed PMID: 28964554]